Merck stakes out 'irritable' neuron territory with $1.25 billion.
Cormac
C
Sheridan
D002986:Clinical Trials as Topic; D003371:Cough / Q000188:drug therapy / Q000503:physiopathology; D004345:Drug Industry / Q000191:economics / Q000458:organization & administration; D006801:Humans; D009474:Neurons; D058920:Purinergic P2X Receptor Antagonists / Q000009:adverse effects / Q000627:therapeutic use; D011743:Pyrimidines / Q000009:adverse effects / Q000627:therapeutic use; D013449:Sulfonamides; D013651:Taste Disorders / Q000139:chemically induced; D000096926:Benzenesulfonamides
D058920:Purinergic P2X Receptor Antagonists; D011743:Pyrimidines; D013449:Sulfonamides; C000597312:Gefapixant; D000096926:Benzenesulfonamides